Joseph Frattaroli's Insider Trades & SAST Disclosures
Joseph Frattaroli's most recent trade in Inhibikase Therapeutics Inc was a trade of 90,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 1, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Joseph Frattaroli.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics Inc | Joseph Frattaroli | Cheif Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Joseph Frattaroli | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 19 May 2022 | 3,948 | 48,091 | - | 0.6 | 2,543 | Common Stock |
| Inhibikase Therapeutics Inc | Joseph Frattaroli | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Joseph Frattaroli | Cheif Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 62,500 | 62,500 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Joseph Frattaroli | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2020 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Inhibikase Therapeutics Inc | Joseph Frattaroli | Chief Financial Officer | 22 Dec 2020 | 44,143 | 44,143 | - | 10 | 441,430 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges